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Abstract  In  the  treatment  of  homozygous  and  therapy-
resistant  hypercholesterolemia,  lipid  apheresis  enables 
not  only  low  density  lipoprotein  (LDL)  cholesterol  to  be 
lowered  by  approximately  60%,  but  also  oxidative  stress 
factors  to  be  influenced  and  adhesion molecules  reduced. 
This  was  investigated  in  a  group  of  12  patients  using 
the  heparin-induced  extracorporeal  LDL  precipitation 
(H.E.L.P.) procedure.
A  significant  lowering of LDL cholesterol  and fibrino-







dure  in  the  treatment of elevated  lipoprotein(a)  [Lp(a)]. A 
chosen group of nine patients with selective elevated Lp(a) 
illustrated both the influence on endothelial dysfunction, in 
the  shape  of  sharply  increased minimum  coronary  resist-
ance, and the reduction through lipid apheresis,  indicating 




Lipid apheresis  is a  tried and tested  therapeutic procedure 






alternative  therapeutic  procedures  are  required,  especially 
in conjunction with advancing coronary artery disease.
Here  lipid  apheresis  represents  a  therapeutic  option. 
Over the past 25 years, various techniques [2] have become 




In  addition  to  lowering LDL  cholesterol,  the  dominant 
factor  in  the  pathogenesis  of  atherosclerosis,  additional 
factors  such  as  oxidative  stress,  adhesion molecules,  and 
fibrinogen, which maintain atherosclerosis, influence endot-








































plasma  concentrations  of OxLDL,  copper/zinc  superoxid-
dismutase  (Cu/ZnSOD),  and  8-isoprostane-PGF2a  were 









The  single  H.E.L.P.  treatment  reduced  the  total  cho-
lesterol  by  53%,  the  LDL  cholesterol  by  54%,  and  the 







Following  the  H.E.L.P.  treatment,  in  most  patients  an 
increase in 8-isoprostane-PGF2a concentration in the serum 
could  be  observed.  It  is  possible  that  the  8-isoprostane-
PGF2a  predominantly  originate  from  the  cell membranes 





H.E.L.P.  apheresis  the  sum  of  antioxidative  effects  is  far 
greater.
Additional effects of lipid apheresis: adhesion molecules























In  each  case,  the  reduction  in  the  plasma  concentration 





Pre Post1 Pre vs. post1 Post2 Pre vs. post2
OxLDL (mU/l) 11.4 ± 6 6.25 ± 3 p < 0.01 10 ± 3 n.s.
MDA (µmol/l) 1.27 ± 0.3 0.9 ± 0.14 p < 0.01 1.25 ± 02 n.s.
ImAnOx (µmol/l) 317 ± 35 287 ± 46 p = 0.03 312 ± 29 n.s.
Cu/ZnSOD (ng/ml) 75 ± 36 71 ± 27 n.s. 64 ± 20 n.s.
















endothelial  function  and  endothelium-dependent  coronary 
vasodilatation  capacity  can be  achieved  through  intensive 
lowering of cholesterol levels [9, 10]. This can be explained 
by the interactions of LDL cholesterol (LDL) and nitrogen 
monoxide  (NO), which  synthesizes  in  the endothelial  cell 
and  is  released from there  [11].  In an oxidized state, high 
LDL  concentrations  reduce  the  bioavailability  of NO  and 
alter the myocardial vascular tone by inhibiting the endothe-
lium-dependent  vasodilatation  conveyed  by  receptors  and 











with  hypercholesterolemia  and  angiographically  docu-
mented  coronary  artery  disease  were  examined.  Thirty-
five patients  (11 women, 24 men, aged 50 ± 8 years) were 
participating  in  the  chronic  lipid  apheresis  program  with 
regular treatments taking place once a week (Group A). The 
mean preceding period of treatment was 53.1 months (5–98 
months). Twelve  patients  (1 woman,  11 men,  aged  47 ± 9 
years)  were  undergoing  lipid  apheresis  for  the  first  time 
(Group  B).  The  lipid  apheresis  was  performed  using  the 
H.E.L.P. procedure.




In  order  to  evaluate  coronary  vasodilatation  capacity, 







commission,  the  first  laboratory  diagnosis was  performed 
on the day of treatment prior to the PET examination (PRE). 
Immediately  after  that,  lipid  apheresis was  performed. At 
the end of the treatment the effectivity was documented by 
a second laboratory diagnosis (POST 1). The next day the 







follow-up  PET  examination  in Group A,  the  reduction  in 
total  cholesterol was 41.3%,  and  in both LDL cholesterol 
and fibrinogen 45.8%.
Immediately  before  the  follow-up  PET  examination  in 
Group B,  the  reduction  in  total cholesterol was 43.2%,  in 
LDL cholesterol 54.6%, and in fibrinogen 51.8%.
The  changes  in  viscosity  in  Group  A  (baseline: 
1.28 ± 0.10 mPa s; at the time of the follow-up PET exami-
nation 1.18 ± 0.08 mPa s,  corresponding  to a  reduction by 
7.8%) were significant (p < 0.01).
In Group B, the baseline viscosity was 1.29 ± 0.08 mPa s. 
At  the  time  of  the  follow-up  PET  examination  it  was 
1,19 ± 0.07 mPa  s,  corresponding  to  a  reduction  by  7.6%. 
This was also significant (p < 0.0075).




Group Cholesterol (mg/dl) LDL cholesterol (mg/dl) Fibrinogen (mg/dl)
PRE POST 1 POST 2 PRE POST 1 POST 2 PRE POST 1 POST 2
A 251 ± 58 120 ± 22 145 ± 28 175 ± 50 60 ± 21 77 ± 25 287 ± 75 102 ± 29 150 ± 52



















Lipoprotein(a)  [Lp(a)]  is  a  fat-protein molecular  complex 
and  consists  of  a  low  density  lipoprotein  (LDL)  particle 
which  is  bound  to  a  glycoprotein  similar  to  plasminogen, 
apolipoprotein(a)  [16].  The  structural  affinity  of  Lp(a)  to 





Since  the  early  1960s,  Lp(a)  has  been  discussed  as  a 
significant  and  independent  risk  factor  for  cardiovascular 
diseases [17].
It could be proven that rising Lp(a) plasma levels are lin-











to  the  second  PET  examination  (reduction:  60.2/55.5%), 
fibrinogen  from  318  to  124  or  164  mg/dl  (reduction: 
61.1/48.5%), viscosity from 1.24 to 1.06 or 1.11 mPa s. The 
Lp(a)  concentration  dropped  from 147  to  50  or  60 mg/dl 
(reduction: 66/59.2%).




and  normal  LDL  concentration,  a  high  MCR  is  particu-
larly conspicuous. A significant  improvement  in perfusion 
was  achieved  through  the  sharp  decrease  brought  about 
by  H.E.L.P.  apheresis.  In  all  probability,  Lp(a)  in  a  high 
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